Daflon

Vein diseases and hemorrhoids

Daflon is not an FDA-approved medication, and therefore it cannot be advertised for treatment of diseases in the United States. Daflon is under preliminary research for its potential use in treating vein diseases, or hemorrhoids. It is sold as a drug in France, Spain, Malaysia, Portugal, Belgium and Egypt.

There is moderate certainty evidence for the effectiveness of daflon for slightly reducing oedema compared to placebo in the treatment of chronic venous insufficiency. Little to no differences in quality of life after treatment with Daflon were found and there is low certainty evidence that this class of drugs do not influence ulcer healing. Diosmiplex, a micronized purified flavonoid fraction of daflon, with similar venous insufficiency indication, is sold as a prescription medical food in the US.

Pharmacological activity

Daflon plays a crucial role in the prevention of perivascular edema formation and treatment of venous stasis. This activity can be explained by its antagonist activity against prostaglandin E2 (PgE2) and thromboxane (TxA2) biosynthesis leading to inhibition of inflammatory process. Moreover, it also has a contraction activity on the lymphatic vessels which cause the lymphatic flow maximal.

Dosage

For venous insufficiency, the dosage is 2 tablets of 500mg daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days. For chronic venous disease, the dosage is 2 tablets a day for at least 2 months.

Side effects

Possible side effects include routine gastric disorders and neurovegetative disorders, however, toxicology studies indicate that diosmin is quite safe. Diosmin interacts in an inhibitory manner with some metabolic enzymes so drug-interactions are probable.

References

References

1. "Offocial Monograph. Daflon 500: Summary of Product Characteristics".
2. (2021-10-23). "Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review". European Journal of Drug Metabolism and Pharmacokinetics.
3. (2016). "Flavonoids: an overview". Journal of Nutritional Science.
4. (2021-10-23). "Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review". European Journal of Drug Metabolism and Pharmacokinetics.
5. Lyseng-Williamson KA, Perry CM. (2003). "Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids". Drugs.
6. (15 August 2012). "Phlebotonics for haemorrhoids". Cochrane Database of Systematic Reviews.
7. "Daflon - EurekaSanté par Vidal".
8. "Notice patient - Daflon 500 mg, comprimé pelliculé - Base de données publique des médicaments".
9. [https://cima.aemps.es/cima/dochtml/p/59080/Prospecto_59080.html Spanish medicines agency (in Spanish)]
10. (2011). "Drug Formulary".
11. Norliza. (2011-09-14). "Kehamilan & Perubatan".
12. (November 3, 2020). "Phlebotonics for venous insufficiency". The Cochrane Database of Systematic Reviews.
13. (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)". Phlebology.
14. Labrid, C.. (June 1994). "Pharmacologic properties of Daflon 500 mg". Angiology.
15. "Diosmin Uses, Benefits & Dosage - Drugs.com Herbal Database".
16. Publishing, Licorn. (2009-11-26). "Benefit of Daflon 500 mg in chronic venous disease-related symptoms".